|
**Overview**: Herpes Simplex Virus 2 Antibodies Panel**Introduction**: The Herpes Simplex Virus 2 Antibodies Panel is a diagnostic tool designed to screen for HSV-2 infection using serum samples. In India, HSV-2 is the primary cause of genital herpes (~10-20 percent adult seroprevalence), with recurrent painful ulcers increasing HIV acquisition risk and neonatal transmission. High morbidity from under-testing in rural/low-SES patients with genital lesions, limited labs, delayed suppressive acyclovir leading to frequent recurrences or transmission. Per microbiology practices aligned with ICMR and IDSP guidelines, the test employs immunoassay for HSV-2 IgG and IgM over 1-2 days with high specificity, valuable for type-specific diagnosis and counseling. This diagnostic falls under viral screening and targets patients with genital ulcers, recurrent lesions, or pregnancy/partner risk, addressing accurate detection to guide therapy and prevention. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise HSV-2 identification and reducing STI burden. Its serum-based approach ensures reliable serology.**Other Names**: HSV 2 Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.**Historical Milestone**: Type-specific HSV-2 serology standard; in India, used in STI clinics.**Purpose**: The test assesses 2 parameters including HSV-2 IgG to guide HSV-2 infection screening, detect past/acute infection, inform suppressive therapy.**Test Parameters**: 1. HSV-2 IgG, 2. HSV-2 IgM.**Pretest Condition**: No fasting required; patients should report genital lesions or recurrence.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on lesion recurrence, partner history, pregnancy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated HSV-2 including transmission/neonatal risk, benefits of detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cross-reactivity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive HSV-2 IgG indicates past infection; IgM positive suggests acute episode, necessitating specialist input.**Specialist Consultation**: Dermatologists or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: HSV PCR from lesions for confirmation.**Test Limitations**: IgM less reliable; comprehensive approach required.**References**: Indian Journal of Dermatology 2024, STI Studies India 2023. |
